BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/14/2026 5:53:05 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-07-13 09:24 |
|
Peer-Review Started |
|
2026-07-13 09:24 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-07-30 08:10 |
|
Revised |
|
2026-08-13 11:56 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-10-09 03:30 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-10-09 09:21 |
|
Articles in Press |
|
2026-10-09 09:21 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-10-12 01:58 |
|
Publish the Manuscript Online |
|
2026-10-14 05:53 |
| ISSN |
1948-5190 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Real-world clinical outcomes, prognostic factors, and safety profile of upadacitinib in patients with inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Vassiliki Kitsou, Georgios Kokkotis, Panagiotis Avatziadis, Alexandros Ioannou, Spyridon Michopoulos, Evanthia Zampeli and Giorgos Bamias |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Giorgos Bamias, MD, PhD, Professor, GI Unit, 3rd Academic Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Mesogeion Avenue 152, Athens 11527, Attikí, Greece. gbamias@gmail.com |
| Key Words |
Upadacitinib; Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Treatment; Drug sustainability; Efficacy |
| Core Tip |
Our real-world study demonstrates that upadacitinib is an effective and well-tolerated treatment for patients with advanced therapy-refractory inflammatory bowel disease. Over a median follow-up of 66 weeks, upadacitinib showed high treatment persistence and clinical remission rates, particularly in patients with ulcerative colitis. Moreover, our study identifies baseline predictors for treatment discontinuation or intensification of upadacitinib in patients with ulcerative colitis, as well as predictors of endoscopic remission in both ulcerative colitis and Crohn’s disease, thus, providing insights into personalized management of patients. |
| Publish Date |
2026-10-14 05:53 |
| Citation |
Kitsou V, Kokkotis G, Avatziadis P, Ioannou A, Michopoulos S, Zampeli E, Bamias G. Real-world clinical outcomes, prognostic factors, and safety profile of upadacitinib in patients with inflammatory bowel disease. World J Gastrointest Endosc 2026; 18(10): 125564
|
| URL |
https://www.wjgnet.com/1948-5190/full/v18/i10/125564.htm |
| DOI |
https://doi.org/10.4253/wjge.125564 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
